{"info": {"address1": "1000 Mylan Boulevard", "city": "Canonsburg", "state": "PA", "zip": "15317", "country": "United States", "phone": "724-514-1800", "website": "https://www.viatris.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.", "fullTimeEmployees": 37000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert J. Coury", "age": 61, "title": "Exec. Chairman", "yearBorn": 1961, "fiscalYear": 2021, "totalPay": 7752068, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rajiv  Malik", "age": 61, "title": "Pres & Exec. Director", "yearBorn": 1961, "fiscalYear": 2021, "totalPay": 4422233, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanjeev  Narula", "age": 61, "title": "Chief Financial Officer", "yearBorn": 1961, "fiscalYear": 2021, "totalPay": 2850674, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Mauro", "age": 49, "title": "Pres of Developed Markets", "yearBorn": 1973, "fiscalYear": 2021, "totalPay": 2849898, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott Andrew Smith", "age": 60, "title": "CEO & Director", "yearBorn": 1962, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanjeev Kumar Sethi", "age": 55, "title": "Chief Operating Officer", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul B. Campbell", "age": 54, "title": "Chief Accounting Officer, Sr. VP & Corp. Controller", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian S. Roman", "age": 52, "title": "Global Gen. Counsel", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Bayles", "title": "Chief Compliance Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Mauer", "title": "Head of Global Communications & Corp. Brand", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 6, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1680307200, "compensationAsOfEpochDate": 1640908800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.91, "open": 9.93, "dayLow": 9.77, "dayHigh": 9.9394, "regularMarketPreviousClose": 9.91, "regularMarketOpen": 9.93, "regularMarketDayLow": 9.77, "regularMarketDayHigh": 9.9394, "dividendRate": 0.48, "dividendYield": 0.0484, "exDividendDate": 1678233600, "payoutRatio": 0.2807, "beta": 1.175778, "trailingPE": 5.744186, "forwardPE": 3.4068966, "volume": 5531811, "regularMarketVolume": 5531811, "averageVolume": 9146704, "averageVolume10days": 8494280, "averageDailyVolume10Day": 8494280, "bid": 0.0, "ask": 0.0, "bidSize": 4000, "askSize": 4000, "marketCap": 11824482304, "fiftyTwoWeekLow": 8.42, "fiftyTwoWeekHigh": 12.4, "priceToSalesTrailing12Months": 0.7270922, "fiftyDayAverage": 10.4794, "twoHundredDayAverage": 10.41955, "trailingAnnualDividendRate": 0.48, "trailingAnnualDividendYield": 0.048435923, "currency": "USD", "enterpriseValue": 30050326528, "profitMargins": 0.12781, "floatShares": 1191907022, "sharesOutstanding": 1196809984, "sharesShort": 24534167, "sharesShortPriorMonth": 20577864, "sharesShortPreviousMonthDate": 1677542400, "dateShortInterest": 1680220800, "sharesPercentSharesOut": 0.020499999, "heldPercentInsiders": 0.0028, "heldPercentInstitutions": 0.79143, "shortRatio": 2.51, "shortPercentOfFloat": 0.0231, "impliedSharesOutstanding": 0, "bookValue": 17.361, "priceToBook": 0.5690916, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1672444800, "netIncomeToCommon": 2078599936, "trailingEps": 1.72, "forwardEps": 2.9, "pegRatio": -0.78, "lastSplitFactor": "3:2", "lastSplitDate": 1065657600, "enterpriseToRevenue": 1.848, "enterpriseToEbitda": 5.271, "52WeekChange": -0.08856088, "SandP52WeekChange": -0.06829989, "lastDividendValue": 0.12, "lastDividendDate": 1678233600, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "VTRS", "underlyingSymbol": "VTRS", "shortName": "Viatris Inc.", "longName": "Viatris Inc.", "firstTradeDateEpochUtc": 322151400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d5d1873c-6bd3-3e7a-85a5-4c85b774dfd9", "messageBoardId": "finmb_290203", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.88, "targetHighPrice": 35.0, "targetLowPrice": 10.0, "targetMeanPrice": 15.63, "targetMedianPrice": 14.0, "recommendationMean": 2.6, "recommendationKey": "hold", "numberOfAnalystOpinions": 11, "totalCash": 1337799936, "totalCashPerShare": 1.118, "ebitda": 5700899840, "totalDebt": 19527700480, "quickRatio": 0.764, "currentRatio": 1.577, "totalRevenue": 16262700032, "debtToEquity": 92.67, "revenuePerShare": 13.417, "returnOnAssets": 0.03393, "returnOnEquity": 0.10002, "grossProfits": 7031900000, "freeCashflow": 3722200064, "operatingCashflow": 2952600064, "revenueGrowth": -0.107, "grossMargins": 0.43238997, "ebitdaMargins": 0.35055, "operatingMargins": 0.17504999, "financialCurrency": "USD", "trailingPegRatio": null}, "news": [{"uuid": "60f4adb3-26f2-3eea-8b42-dddbdd928736", "title": "Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/viatris-vtrs-stock-sinks-market-221510986.html", "providerPublishTime": 1681856110, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/kz0ozt3ejWMPXKci2JxOBw--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9", "width": 1000, "height": 754, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/9DuI9CAB81x7COnzMbUTGw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["VTRS"]}, {"uuid": "899a3f78-5ab5-3730-8444-ff16b5d56d79", "title": "Should You Hold Viatris (VTRS)?", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/hold-viatris-vtrs-063936534.html", "providerPublishTime": 1681799976, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/givXnSAoqABBVIZLpXjBVA--~B/aD02Njg7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/382f812a97a6f4b17398b231c6857399", "width": 1000, "height": 668, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/FeQGE2K0tqB9aubagDXAFg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/382f812a97a6f4b17398b231c6857399", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["VTRS"]}, {"uuid": "f865b44d-1b2e-3542-ae64-f483332476fd", "title": "UPDATE 2-US Supreme Court spurns Sanofi appeal to revive EpiPen suit against Viatris", "publisher": "Reuters", "link": "https://finance.yahoo.com/news/1-us-supreme-court-spurns-134959492.html", "providerPublishTime": 1681739399, "type": "STORY", "relatedTickers": ["VTRS", "SNY"]}, {"uuid": "345985d1-0ace-38fe-92f4-1d370b08c8ef", "title": "US Supreme Court spurns Sanofi appeal to revive EpiPen suit against Viatris", "publisher": "Reuters", "link": "https://finance.yahoo.com/news/us-supreme-court-spurns-sanofi-134245330.html", "providerPublishTime": 1681738965, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/VuiZAR3XJIWkL0O_bjautg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/24823971b4c15983a590a3341816a1ee", "width": 800, "height": 533, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/OQoMWmOcLy1RQ_rSJcrNNQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/reuters-finance.com/24823971b4c15983a590a3341816a1ee", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["SNY", "VTRS"]}, {"uuid": "41248947-690b-3331-bc0d-b47c7a8c7dcb", "title": "Wall Street Thinks These 2 Value Stocks Could Soar", "publisher": "Motley Fool", "link": "https://finance.yahoo.com/m/41248947-690b-3331-bc0d-b47c7a8c7dcb/wall-street-thinks-these-2.html", "providerPublishTime": 1681730100, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/hhexIN72VjqzM9I9EqN6DQ--~B/aD0xNDAxO3c9MjE0MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/fcc80b75a030380d4e897c8e1b19a160", "width": 2140, "height": 1401, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/PYC4hmTdwHf8zFJ1zGTS6w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/fcc80b75a030380d4e897c8e1b19a160", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["VTRS", "CNC"]}, {"uuid": "83bb15ae-89c1-3544-a6ea-2b27189fee68", "title": "1 \"Safe\" Stock to Avoid and 1 to Consider Buying in April", "publisher": "Motley Fool", "link": "https://finance.yahoo.com/m/83bb15ae-89c1-3544-a6ea-2b27189fee68/1-%22safe%22-stock-to-avoid-and-1.html", "providerPublishTime": 1681563360, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/tnMPFKHYQbhSoYTCXgUbyA--~B/aD0xNDE0O3c9MjExOTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/18c38fb3c576cab0efaeb7d4a7820d0b", "width": 2119, "height": 1414, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Tcf7NBwMm88zYIHVzvD._Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/18c38fb3c576cab0efaeb7d4a7820d0b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["TEVA", "VTRS"]}, {"uuid": "b072de1e-f76a-38f1-bc11-16fc4d9178ad", "title": "UPDATE 1-Teva, Viatris win U.S. appeal in patent fight over Parkinson's drug", "publisher": "Reuters", "link": "https://finance.yahoo.com/news/1-teva-viatris-win-u-203314138.html", "providerPublishTime": 1681331594, "type": "STORY", "relatedTickers": ["VTRS"]}, {"uuid": "32a534a1-aced-36dd-8409-534d0756a415", "title": "Teva, Viatris win U.S. appeal in patent fight over Parkinson's drug", "publisher": "Reuters", "link": "https://finance.yahoo.com/news/teva-viatris-win-u-appeal-183253395.html", "providerPublishTime": 1681324373, "type": "STORY", "relatedTickers": ["VTRS", "TEVA"]}]}